Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Specific ancient viral DNA sequences in the human genome are linked to genetic risk for multiple sclerosis and amyotrophic ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

DAZALS is being conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig’s disease, is a fatal degenerative neurologic ...